{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:55:36Z","timestamp":1782741336626,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40123-026-01384-3","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:11:12Z","timestamp":1778861472000},"page":"2213-2229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8506-8503","authenticated-orcid":false,"given":"Kenji","family":"Kashiwagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2632-8808","authenticated-orcid":false,"given":"Miyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4517-9163","authenticated-orcid":false,"given":"Rikiya","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5778-1943","authenticated-orcid":false,"given":"Kana","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Michikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"9","key":"1384_CR1","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, et\u00a0al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111(9):1641\u20138.","journal-title":"Ophthalmology"},{"issue":"10","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.ophtha.2005.05.012","volume":"112","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Iwase A, Araie M, et\u00a0al. The Tajimi Study report 2: prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology. 2005;112(10):1661\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2019","unstructured":"Morizane Y, Morimoto N, Fujiwara A, et\u00a0al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63(1):26\u201333.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"1384_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10384-023-00986-9","volume":"67","author":"R Matoba","year":"2023","unstructured":"Matoba R, Morimoto N, Kawasaki R, et\u00a0al. A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification. Jpn J Ophthalmol. 2023;67(3):346\u201352.","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, et\u00a0al. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67(2):189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"issue":"12","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Holl\u00f3","year":"2014","unstructured":"Holl\u00f3 G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014;15(12):1737\u201347.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"1384_CR7","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s40123-023-00730-z","volume":"12","author":"L Quaranta","year":"2023","unstructured":"Quaranta L, Novella A, Tettamanti M, et\u00a0al. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol Ther. 2023;12(5):2227\u201340.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","volume":"58","author":"K Kashiwagi","year":"2014","unstructured":"Kashiwagi K, Furuya T. Persistence with topical glaucoma therapy among newly diagnosed Japanese patients. Jpn J Ophthalmol. 2014;58(1):68\u201374.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12886-020-01508-8","volume":"20","author":"K Kashiwagi","year":"2020","unstructured":"Kashiwagi K, Chono E, Koesters S, et\u00a0al. Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan. BMC Ophthalmol. 2020;20(1):223.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"1384_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12886-021-01813-w","volume":"21","author":"C Shirai","year":"2021","unstructured":"Shirai C, Matsuoka N, Nakazawa T. Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare\/pharmacy claims database: a retrospective non-interventional cohort study. BMC Ophthalmol. 2021;21(1):52.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"1384_CR11","first-page":"11","volume":"27","author":"A Okada","year":"2022","unstructured":"Okada A, Yasunaga H. Overview of the DeSC database and utilization for clinical epidemiology and pharmacoepidemiology research. Jpn J Pharmacoepidemiol. 2022;27(1):11\u20138 (in Japanese).","journal-title":"Jpn J Pharmacoepidemiol"},{"issue":"11","key":"1384_CR12","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.11.11.11","volume":"11","author":"K Fujiwara","year":"2022","unstructured":"Fujiwara K, Yasuda M, Hata J, et\u00a0al. Prevalence of glaucoma and its systemic risk factors in a general Japanese population: the Hisayama study. Transl Vis Sci Technol. 2022;11(11):11.","journal-title":"Transl Vis Sci Technol"},{"issue":"8","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.ophtha.2019.02.003","volume":"126","author":"CG De Moraes","year":"2019","unstructured":"De Moraes CG. Natural history of normal-tension glaucoma with (very) low intraocular pressure. Ophthalmology. 2019;126(8):1117\u20138.","journal-title":"Ophthalmology"},{"issue":"3","key":"1384_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s40266-015-0250-4","volume":"32","author":"SL Greig","year":"2015","unstructured":"Greig SL, Deeks ED. Brinzolamide\/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension. Drugs Aging. 2015;32(3):251\u201360.","journal-title":"Drugs Aging"},{"key":"1384_CR15","first-page":"117","volume":"3","author":"A Galanopoulos","year":"2009","unstructured":"Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:117\u201322.","journal-title":"Clin Ophthalmol"},{"key":"1384_CR16","unstructured":"Santen Pharmaceutical Co. Ltd. Trusopt (dorzolamide hydrochloride) opthalmic solution 0.5% [Japanese drug information sheet]. 2023. https:\/\/www.rad-ar.or.jp\/siori\/english\/search\/result?n=34753. Accessed 3 Nov 2025."},{"issue":"1","key":"1384_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, et\u00a0al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129\u201340.","journal-title":"Ophthalmology"},{"issue":"3","key":"1384_CR18","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1111\/aos.13568","volume":"96","author":"F Li","year":"2018","unstructured":"Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277\u201384.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1097\/OPX.0000000000000542","volume":"92","author":"N Ramli","year":"2015","unstructured":"Ramli N, Supramaniam G, Samsudin A, et\u00a0al. Ocular surface disease in glaucoma: effect of polypharmacy and preservatives. Optom Vis Sci. 2015;92(9):e222\u20136.","journal-title":"Optom Vis Sci"},{"issue":"2","key":"1384_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","volume":"36","author":"MH Goldstein","year":"2022","unstructured":"Goldstein MH, Silva FQ, Blender N, et\u00a0al. Ocular benzalkonium chloride exposure: problems and solutions. Eye (Lond). 2022;36(2):361\u20138.","journal-title":"Eye (Lond)"},{"key":"1384_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/PPA.S23780","volume":"5","author":"G Reardon","year":"2011","unstructured":"Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011;5:441\u201363.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1384_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010151","volume":"12","author":"B Cvenkel","year":"2022","unstructured":"Cvenkel B, Kolko M. Devices and treatments to address low adherence in glaucoma patients: a narrative review. J Clin Med. 2022;12(1):151.","journal-title":"J Clin Med"},{"issue":"2","key":"1384_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.pec.2011.09.009","volume":"87","author":"KW Muir","year":"2012","unstructured":"Muir KW, Ventura A, Stinnett SS, et\u00a0al. The influence of health literacy level on an educational intervention to improve glaucoma medication adherence. Patient Educ Couns. 2012;87(2):160\u20134.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"1384_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00417-021-05357-z","volume":"260","author":"A Kido","year":"2022","unstructured":"Kido A, Miyake M, Akagi T, et\u00a0al. Association between topical \u03b2-blocker use and asthma attacks in glaucoma patients with asthma: a cohort study using a claims database. Graefes Arch Clin Exp Ophthalmol. 2022;260(1):271\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01384-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01384-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01384-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:23:26Z","timestamp":1782739406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01384-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01384-3","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kenji Kashiwagi reports receiving consulting fees from Otsuka Pharmaceutical Co., Ltd., Novartis, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd. and Kowa Company, Ltd. Miyuki Matsukawa, Rikiya Toda, Kana Okamoto and Daisaku Michikami are employees of Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study used anonymised, pre-existing insurance claims data and did not involve the collection of new personal information or any direct interaction with patients. As such, it was not subject to the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects in Japan, and informed consent was not required. An application for ethical review was submitted to the Research Ethics Committee of Otsuka Pharmaceutical Co., Ltd., which judged that no review was required (a notice of No Review [#001] was received). The study complied with the Act on the Protection of Personal Information (Act No. 57 of 2003, as amended) and all relevant subordinate regulations and guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}